Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma

Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 155(2014), 2 vom: 22. Dez., Seite 176-87
1. Verfasser: Berkowitz, Jonathan L (VerfasserIn)
Weitere Verfasser: Janik, John E, Stewart, Donn M, Jaffe, Elaine S, Stetler-Stevenson, Maryalice, Shih, Joanna H, Fleisher, Thomas A, Turner, Maria, Urquhart, Nicole E, Wharfe, Gilian H, Figg, William D, Peer, Cody J, Goldman, Carolyn K, Waldmann, Thomas A, Morris, John C
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, N.I.H., Intramural Adult T-cell leukemia/lymphoma Daclizumab Human T-cell leukemia virus 1 (HTLV-1) associated ATL Interleukin-2 receptor alpha Monoclonal antibody Antibodies, Monoclonal, Humanized mehr... Antineoplastic Agents Immunoglobulin G Interleukin-2 Receptor alpha Subunit CUJ2MVI71Y
Beschreibung
Zusammenfassung:Published by Elsevier Inc.
Interleukin-2 receptor α chain (CD25) is overexpressed in human T-cell leukemia virus 1 associated adult T-cell leukemia/lymphoma (ATL). Daclizumab a humanized monoclonal antibody blocks IL-2 binding by recognizing the interleukin-2 receptor α chain (CD25). We conducted a phase I/II trial of daclizumab in 34 patients with ATL. Saturation of surface CD25 on circulating ATL cells was achieved at all doses; however saturation on ATL cells in lymph nodes required 8 mg/kg. Up to 8 mg/kg of daclizumab administered every 3 weeks was well tolerated. No responses were observed in 18 patients with acute or lymphoma ATL; however, 6 partial responses were observed in 16 chronic and smoldering ATL patients. The pharmacokinetics/pharmacodynamics of daclizumab suggest that high-dose daclizumab would be more effective than low-dose daclizumab in treatment of lymphoid malignancies and autoimmune diseases (e.g., multiple sclerosis) since high-dose daclizumab is required to saturate IL-2R alpha in extravascular sites
Beschreibung:Date Completed 19.02.2015
Date Revised 11.05.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2014.09.012